• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IRIDEX Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    5/20/25 5:26:27 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    false 0001006045 0001006045 2025-05-14 2025-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    May 14, 2025

    Date of Report (date of earliest event reported)

     

    IRIDEX CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware   000-27598   77-0210467
    (State or other jurisdiction of
    incorporation or organization)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

    1212 Terra Bella Avenue
    Mountain View, California 94043

    (Address of principal executive offices, including zip code)

     

    (650) 940-4700

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☒Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Class   Trading Symbol   Name of Exchange on Which Registered
    Common Stock, par value $0.01 per share   IRIX   Nasdaq Capital Market

     

     

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On May 14, 2025, IRIDEX Corporation (the “Company”) received a notification of non-compliance (the “Notice”) from Nasdaq’s Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon its Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2025 that was filed with the Securities and Exchange Commission (the “SEC”) on May 13, 2025, the Company is not in compliance with the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). As described in the Notice, the Company’s last reported stockholders’ equity as of March 29, 2025, was approximately $852,000 and, as of May 14, 2025, the Company does not meet the alternative listing requirements of its market value of listed securities or its net income from continuing operations in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

     

    The Notice arises in part due to the Company’s Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), which the Company sold to Novel Inspiration International Co. Ltd., earlier this year in March for aggregate proceeds of $6,000,000, being classified as “temporary equity.” The sale of the Series B Preferred Stock was previously disclosed on the Current Report on Form 8-K filed by the Company on March 20, 2025.

     

    The Company is already seeking stockholder approval at its annual meeting of stockholders to be held on June 11, 2025, to approve a proposal (the “Restated Charter Proposal”) to amend and restate the Company’s Amended and Restated Certificate of Incorporation in the form of the Amended and Restated Certificate of Incorporation attached as Appendix A (the “Restated Charter”) to its definitive proxy statement filed with the SEC on April 28, 2025. Among other matters, the Restated Charter amends and restates certain rights of the Series B Preferred Stock in a manner that would result in the Series B Preferred Stock being classified as “permanent equity.” The Company expects that should the stockholders approve the Restated Charter, then upon the filing of the Restated Charter, the Series B Preferred Stock would be reclassified as “permanent equity,” which would result in the Company regaining compliance with Nasdaq’s Stockholders’ Equity Requirement.

     

    In accordance with applicable Nasdaq procedures, within 45 calendar days from receipt of the Notice, or June 30, 2025, the Company intends to submit a plan to the Staff advising it of the definitive action(s) the Company has taken, is taking, or plans to take that would bring it into conformity with the Stockholders’ Equity Requirement (the “Compliance Plan”), including the foregoing plan relating to seeking stockholder approval of the Restated Charter Proposal and, if approved by the stockholders, to file the Restated Charter that would result in the Series B Preferred Stock being reclassified as “permanent equity.” If the Compliance Plan is acceptable to the Staff, of which there can be no assurance, the Staff may grant an extension of up to 180 calendar days of receipt of the Notice to evidence compliance (the “Cure Period”). If the Staff does not accept the Compliance Plan, the Company will have the opportunity to appeal the Staff’s determination to a Nasdaq Hearings Panel pursuant to Nasdaq Listing Rule 5815(a).

     

    The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on Nasdaq during the Cure Period, subject to Nasdaq’s acceptance of the Compliance Plan, the Company’s continued compliance with the Compliance Plan and Nasdaq’s other continued listing requirements.

     

    The current noncompliance with the Nasdaq listing requirements does not affect the Company’s ongoing business operations or its SEC reporting requirements. In addition to the above plan to have the Series B Preferred Stock reclassified as “permanent equity,” the Company is considering other available options to regain compliance with Nasdaq’s continued listing requirements. However, there can be no assurance that the Company will be able to regain compliance with the Stockholders’ Equity Requirement or will otherwise be in compliance with the Nasdaq Listing Rules.

     

    1

     

     

    Important Additional Information Filed with the SEC

     

    The Company has filed with the SEC proxy statements (as amended or supplemented from time to time, the “proxy statements”). BEFORE MAKING ANY VOTING DECISION, IRIDEX’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENTS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE RESTATED CHARTER PROPOSAL AND THE FILING OF THE RESTATED CHARTER AND ANY OTHER PROPOSALS FOR WHICH STOCKHOLDER APPROVAL IS BEING REQUESTED IS DESCRIBED THEREIN OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENTS (IF ANY) CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE RESTATED CHARTER PROPOSAL, THE RESTATED CHARTER AND THE OTHER PROPOSALS FOR WHICH STOCKHOLDER APPROVAL IS BEING REQUESTED. Iridex’s stockholders and investors may obtain, without charge, a copy of the proxy statements and other relevant documents filed with the SEC (when available) from the SEC’s website at www.sec.gov. The proxy statement, proxy solicitation materials can be accessed directly at www.edocumentview.com/irix.

     

    Participants in the Solicitation

     

    Iridex, certain of its directors and executive officers and employees, and our proxy solicitor, Alliance Advisors, LLC, may be considered participants in the solicitation of proxies from the stockholders of Iridex in respect of the stockholder approvals. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the stockholders of Iridex in respect of the stockholder approvals, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the proxy statement filed with the SEC. Information regarding Iridex’s directors and executive officers is contained in Iridex’s Annual Report on Form 10-K for the fiscal year ended December 28, 2024 filed with the SEC, its Definitive Proxy Statement on Schedule 14A filed with the SEC on April 28, 2025, and its Proxy Supplement filed with the SEC on May 20, 2025.

     

    Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of the Company’s stockholders in connection with the Restated Charter Proposal and related matters and any other matters to be voted upon at the annual meeting are set forth in the proxy statements filed with the SEC. These documents are available free of charge as described in the preceding section.

     

    Forward-Looking Statements, Risks and Uncertainties

     

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Privates Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding the Company’s ability to develop or submit a plan to regain compliance with Nasdaq’s continued listing criteria, Nasdaq’s acceptance of such plan, the Company’s ability to execute such plan and to continue to comply with the applicable listing standards within the applicable cure period and remain listed on Nasdaq, risks arising from the potential suspension of trading of the Company’s common stock on Nasdaq, the Company’s ability to obtain stockholder approval for the Restated Charter Proposal, the Company’s plan to file the Restated Charter and the resulting reclassification of the Series B Preferred Stock into “permanent equity,” and other risks and uncertainties detailed from time to time in the Company’s reports filed with the SEC.

     

    Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “believe,” “may,” “will,” “continue,” “anticipate,” “assume,” “plans,” “intends” or similar expressions and the negatives of those terms. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Investors are cautioned not to place undue reliance on the forward-looking statements. All information provided in this Current Report on Form 8-K and in the exhibits is as of the date hereof and is based on then-current expectations and the beliefs and assumptions of management. We undertake no duty to update this information unless required by law.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      IRIDEX CORPORATION
         
      By: /s/ Patrick Mercer
        Patrick Mercer
        Chief Executive Officer
         
    Date: May 20, 2025    

     

     

    3 

     

     

    Get the next $IRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    SEC Filings

    See more
    • SEC Form S-8 filed by IRIDEX Corporation

      S-8 - IRIDEX CORP (0001006045) (Filer)

      6/13/25 5:12:55 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IRIDEX Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IRIDEX CORP (0001006045) (Filer)

      6/13/25 4:38:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by IRIDEX Corporation

      DEFA14A - IRIDEX CORP (0001006045) (Filer)

      6/2/25 4:06:37 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moore William M bought $19,372 worth of shares (20,000 units at $0.97), increasing direct ownership by 12% to 188,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/16/25 1:44:46 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Mercer Patrick bought $240 worth of shares (250 units at $0.96), increasing direct ownership by 0.06% to 386,730 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 2:43:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Moore William M bought $29,121 worth of shares (30,000 units at $0.97), increasing direct ownership by 22% to 168,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 1:28:06 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      5/12/21 11:32:01 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on IRIDEX with a new price target

      Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/9/21 8:09:06 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/3/21 12:29:03 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Iridex Appoints Patrick Mercer as Chief Executive Officer

      MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

      10/3/24 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

      MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

      1/24/24 8:00:00 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces the Appointment of Beverly Huss to its Board of Directors

      MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

      3/21/22 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Financials

    Live finance-specific insights

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Host Strategic Vision Call on April 16, 2025

      MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel's strategic vision for the Company following Novel's recent strategic investment in Iridex. The Company's management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live an

      4/9/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      11/23/22 4:57:01 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      9/20/22 2:06:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

      SC 13G/A - IRIDEX CORP (0001006045) (Subject)

      2/10/22 8:17:17 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vicarious Surgical Announces Election of New Directors

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting. "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and th

      6/30/25 6:45:00 AM ET
      $GSAT
      $IRIX
      $JNJ
      $MITK
      Telecommunications Equipment
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

      MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-vascular endothelial growth factor (anti-VEGF) therapy in patients presenting with severe diabetic macular edema (DME). Led by Principal Investigator Professor Noemi Lois at Que

      6/24/25 7:00:00 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Shuda Scott

      4/A - IRIDEX CORP (0001006045) (Issuer)

      6/24/25 8:27:45 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 4 filed by Director Huss Beverly A

      4/A - IRIDEX CORP (0001006045) (Issuer)

      6/24/25 8:23:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Chen Yu-Hao

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/24/25 8:21:29 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care